Gadoversetamide Brand Name– Optimark
What is Gadoversetamide
Gadoversetamide is a gadolinium-based paramagnetic contrast agent used during diagnostic magnetic resonance imaging to enhance visualization of abnormal vascularity within the central nervous system (CNS) or liver and detect blood-brain barrier disruptions.
Approval was based on the results of 4 clinical trials (2 CNS and 2 hepatic). In all 4 trials, gadoversetamide MRI images (viewed in combination with non-contrast images) significantly improved lesion visualization as compared non-contrast images alone.
These results were based on the readers ability to delineate lesion boarders, identify the number of lesion, the readers confidence in number of lesions, as well as the level of conspicuity of all lesions.
Gadoversetamide, like all gadolinium-based contrast agents (GBCAs), carries a black box warning for nephrogenic systemic fibrosis (NSF). NSF is a serious condition that may result in fatal or debilitating fibrosis of the skin, muscle and internal organs.
The propensity to cause NSF differs among available GBCAs, with gadoversetamide being one of the agents associated with the most unconfounded cases.
Gadoversetamide was FDA-approved in December 1999
Indications
- magnetic resonance imaging (MRI)
For use with magnetic resonance imaging (MRI) to enhance visualization of abnormal vascularity within the central nervous system (CNS) and liver and detect blood-brain barrier disruptions
Side Effects
- abdominal pain
- agitation
- anaphylactoid reactions
- anorexia
- anxiety
- arrhythmia exacerbation
- arthralgia
- asthenia
- back pain
- bronchospasm
- chest pain (unspecified)
- confusion
- constipation
- cough
- diarrhea
- diplopia
- dizziness
- drowsiness
- dysgeusia
- dyspepsia
- dysphagia
- dysphonia
- dyspnea
- edema
- eructation
- erythema multiforme
- fever
- headache
- hypercalcemia
- hyperhidrosis
- hypersalivation
- hypertension
- hypertonia
- hypotension
- injection site reaction
- laryngeal edema
- malaise
- muscle cramps
- myalgia
- nausea
- nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy)
- oliguria
- pallor
- palpitations
- paresthesias
- parosmia
- pelvic pain
- peripheral vasodilation
- pharyngitis
- phlebitis
- polydipsia
- pruritus
- rash
- renal failure (unspecified)
- rhinitis
- seizures
- sinus tachycardia
- sinusitis
- syncope
- tinnitus
- tremor
- urticaria
- vertigo
- vomiting
- xerostomia
Monitoring Parameters
- serum creatinine/BUN
Contraindications
- asthma
- atopy
- breast-feeding
- diabetes mellitus
- dialysis
- extravasation
- geriatric
- hypertension
- laboratory test interference
- magnetic resonance imaging (MRI)
- nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy)
- pregnancy
- radiopaque contrast media hypersensitivity
- renal disease
- renal failure
- renal impairment
- sickle cell disease
Interactions
- Bictegravir; Emtricitabine; Tenofovir Alafenamide
- Darunavir; Cobicistat; Emtricitabine; Tenofovir alafenamide
- Elvitegravir; Cobicistat; Emtricitabine; Tenofovir Alafenamide
- Emtricitabine; Rilpivirine; Tenofovir alafenamide
- Emtricitabine; Tenofovir alafenamide
- Tenofovir Alafenamide
- Tenofovir Alafenamide
